Cassava Sciences, Inc. (SAVA): Price and Financial Metrics
GET POWR RATINGS... FREE!
SAVA Stock Price Chart Interactive Chart >
SAVA Price/Volume Stats
| Current price | $30.44 | 52-week high | $146.16 |
| Prev. close | $30.80 | 52-week low | $15.72 |
| Day low | $29.42 | Volume | 1,219,700 |
| Day high | $31.57 | Avg. volume | 1,685,148 |
| 50-day MA | $24.07 | Dividend yield | N/A |
| 200-day MA | $41.45 | Market Cap | 1.22B |
Cassava Sciences, Inc. (SAVA) Company Bio
Cassava Sciences, Inc. develops drugs using its proprietary technology. The Company develops safer and efficacious drugs for use in pain management, particularly in the area of opioid painkillers. Cassava Sciences has products in clinical trials.
Latest SAVA News From Around the Web
Below are the latest news stories about Cassava Sciences Inc that investors may wish to consider to help them evaluate SAVA as an investment opportunity.
10 Most Shorted Stocks Right NowIn this article, we discuss the 10 most shorted stocks right now. If you want to skip our detailed analysis of these stocks, go directly to the 5 Most Shorted Stocks Right Now. The beginning of 2021 had pitted retail investors against hedge funds in a short squeeze saga involving video game firm GameStop and […] |
We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash WiselyThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining... |
Cassava Sciences: Enormous Upside If Pipeline Is SuccessfulI am neutral on Cassava Sciences (SAVA) as it has enormous upside potential if it can successfully develop its pipeline, Wall Street analysts are unanimously bullish on it, and the average price target implies it could triple over the next year. On the other hand, the company is not yet profitable and remains highly speculative. Cassava Sciences was formed in 1998, and it is headquartered in Texas, United States. The company operates as a clinical-stage biotechnology company in the industry, with a primary focus on neurodegenerative diseases, such as Alzheimer's. |
Cassava Sciences, Inc. (SAVA) Gains But Lags Market: What You Should KnowCassava Sciences, Inc. (SAVA) closed the most recent trading day at $49.22, moving +1.07% from the previous trading session. |
Cassava Sciences (SAVA) Receives a Buy from Maxim GroupMaxim Group analyst Jason McCarthy maintained a Buy rating on Cassava Sciences (SAVA – Research Report) yesterday and set a price target of $110.00. The company's shares closed last Friday at $49.59, close to its 52-week low of $31.44. According to TipRanks.com, McCarthy has 0 stars on 0-5 stars ranking scale with an average return of -23.3% and a 18.4% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Appili Therapeutics Inc Class A, Reviva Pharmaceuticals Holdings, and Brainstorm Cell Therapeutics. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cassava Sciences with a $102. |
SAVA Price Returns
| 1-mo | 14.18% |
| 3-mo | -24.17% |
| 6-mo | -31.60% |
| 1-year | -61.18% |
| 3-year | 2,415.70% |
| 5-year | 637.05% |
| YTD | -30.34% |
| 2021 | 540.76% |
| 2020 | 31.15% |
| 2019 | 511.76% |
| 2018 | -78.75% |
| 2017 | 0.25% |
Loading social stream, please wait...